Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
165 results
Cited 12 times since 2011 (0.9 per year) source: EuropePMC
Circulation. Cardiovascular imaging, Volume 4, Issue 2, 5 1 2011, Pages 122-129 Intramyocardial bone marrow-derived mononuclear cell injection for chronic myocardial ischemia: the effect on diastolic function. van Ramshorst J, Antoni ML, Beeres SL, Roes SD, Delgado V, Rodrigo SF, de Roos A, Holman ER, Fibbe WE, Lamb HJ, Zwaginga JJ, Boersma E, van der Wall EE, Schalij MJ, Atsma DE, Bax JJ
Background: The present substudy of a recently published randomized trial aimed to investigate the effect of intramyocardial bone marrow cell injection on diastolic function in patients with chronic myocardial ischemia. Methods and results: In a total of 50 patients, diastolic function was evaluated before and 3 months after bone marrow cell injection using standard echocardiography and strain analysis. In addition, MRI-derived transmitral flow measurements were obtained in a subset of 36 patien... Abstract
Cited 10 times since 2010 (0.7 per year) source: EuropePMC
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 18, Issue 9, 1 1 2010, Pages 408-415 Standardised pre-hospital care of acute myocardial infarction patients: MISSION! guidelines applied in practice. Atary JZ, de Visser M, van den Dijk R, Bosch J, Liem SS, Antoni ML, Bootsma M, Viergever EP, Kirchhof CJ, Padmos I, Sedney MI, van Exel HJ, Verwey HF, Atsma DE, van der Wal EE, Jukema JW, Schalij MJ
Background. To improve acute myocardial infarction (AMI) care in the region 'Hollands-Midden' (the Netherlands), a standardised guideline-based care program was developed (MISSION!). This study aimed to evaluate the outcome of the pre-hospital part of the MISSION! program and to study potential differences in pre-hospital care between four areas of residency.Methods. Time-to-treatment delays, AMI risk profile, cardiac enzymes, hospital stay, in-hospital mortality, and pre-AMI medicatio... Abstract
Cited 3 times since 2010 (0.2 per year) source: EuropePMC
Minerva medica, Volume 101, Issue 4, 1 1 2010, Pages 255-270 Young at heart. An update on cardiac regeneration. Smits AM, Ramkisoensing AA, Atsma DE, Goumans MJ
Cardiovascular disease remains one of the most important causes of mortality. Over the past decades important advances have been made in prevention and treatment of acute complications after myocardial infarction (MI). As a result, the number of patients that acutely die from MI has been reduced. Current treatments can not prevent the loss of cardiac contractility caused by cardiomyocyte death, and therefore patients that do survive MI are prone to develop progressive impaired cardiac function,... Abstract
Cited 33 times since 2010 (2.4 per year) source: EuropePMC
The American journal of cardiology, Volume 106, Issue 1, 13 2 2010, Pages 4-12 Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). Atary JZ, van der Hoeven BL, Liem SS, Jukema JW, van der Bom JG, Atsma DE, Bootsma M, Zeppenfeld K, van der Wall EE, Schalij MJ
To compare the long-term efficacy and safety of sirolimus-eluting stents (SES) to those of bare-metal stents (BMS) for ST-segment elevation myocardial infarction, outcomes were assessed in 310 patients (mean age age 59 +/- 11 years, 78% men) included in the randomized MISSION! Intervention Study: A Prospective Randomised Controlled Trial to Evaluate the Efficacy of Drug-Eluting Stents Versus Bare-Metal Stents for the Treatment of Acute Myocardial Infarction after a median follow-up period of 38... Abstract
Cited 14 times since 2010 (1 per year) source: EuropePMC
Journal of biomedicine & biotechnology, Volume 2010, 22 4 2010, Pages 702836 Novel approaches to treat experimental pulmonary arterial hypertension: a review. Umar S, Steendijk P, Ypey DL, Atsma DE, van der Wall EE, Schalij MJ, van der Laarse A
Background: Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by an increase in pulmonary artery pressure leading to right ventricular (RV) hypertrophy, RV failure, and ultimately death. Current treatments can improve symptoms and reduce severity of the hemodynamic disorder but gradual deterioration in their condition often necessitates a lung transplant. Methods and results: In experimental models of PAH, particularly the model of monocrotaline-induced pulmonary... Abstract
Cited 41 times since 2010 (2.9 per year) source: EuropePMC
Circulation. Arrhythmia and electrophysiology, Volume 3, Issue 2, 9 2 2010, Pages 126-133 Arrhythmogenic right ventricular dysplasia/cardiomyopathy diagnostic task force criteria: impact of new task force criteria. Cox MG, van der Smagt JJ, Noorman M, Wiesfeld AC, Volders PG, van Langen IM, Atsma DE, Dooijes D, Houweling AC, Loh P, Jordaens L, Arens Y, Cramer MJ, Doevendans PA, van Tintelen JP, Wilde AA, Hauer RN
Background: Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C) Diagnostic Task Force Criteria (TFC) proposed in 1994 are highly specific but lack sensitivity. A new international task force modified criteria to improve diagnostic yield. A comparison of diagnosis by 1994 TFC versus newly proposed criteria in 3 patient groups was conducted. Methods and results: In new TFC, scoring by major and minor criteria is maintained. Structural abnormalities are quantified and TFC highly spec... Abstract
Cited 9 times since 2010 (0.6 per year) source: EuropePMC
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, Volume 26, Issue 6, 1 1 2010, Pages 999-1010 Integrin stimulation favors uptake of macromolecules by cardiomyocytes in vitro. Swildens J, de Vries AA, Li Z, Umar S, Atsma DE, Schalij MJ, van der Laarse A
Previously, our research group showed that integrin stimulation induces release of cardiac troponin I from viable neonatal rat ventricular cardiomyocytes (NRCMs), but would it also stimulate uptake of exogenous macromolecules? For this purpose, beating NRCMs were incubated without or with an RGD motif-containing peptide (GRGDS) to stimulate integrins in the presence of Texas Red-conjugated ovalbumin (OTR; 45 kDa) or dextran (DTR; 70 kDa). After incubation periods of 8, 16 and 24 hours endocytosi... Abstract
Cited 42 times since 2009 (2.9 per year) source: EuropePMC
European heart journal, Volume 31, Issue 7, 16 3 2009, Pages 842-848 The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening. Christiaans I, Birnie E, van Langen IM, van Spaendonck-Zwarts KY, van Tintelen JP, van den Berg MP, Atsma DE, Helderman-van den Enden AT, Pinto YM, Hermans-van Ast JF, Bonsel GJ, Wilde AA
Aims: We investigated the presence of a clinical diagnosis of hypertrophic cardiomyopathy (HCM) and of risk factors for sudden cardiac death (SCD) at the first cardiological evaluation after predictive genetic testing in asymptomatic carriers of an MYBPC3 gene mutation. Methods and results: Two hundred and thirty-five mutation carriers were cardiologically evaluated on the presence of HCM and risk factors. A clinical diagnosis of HCM was made in 53 carriers (22.6%). Disease penetrance at 65 year... Abstract
Cited 4 times since 2009 (0.3 per year) source: EuropePMC
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Volume 5, Issue 5, 1 1 2009, Pages 565-572 Impact of sirolimus-eluting stent implantation compared to bare-metal stent implantation for acute myocardial infarction on coronary plaque composition at nine months follow-up: a Virtual Histology intravascular ultrasound analysis. Results from the Leiden MISSION! intervention study. Atary JZ, Bergheanu SC, van der Hoeven BL, Atsma DE, Bootsma M, van der Kley F, Zeppenfeld K, Jukema JW, Schalij MJ
Aims: To evaluate effects of sirolimus-eluting stents (SES) compared to bare-metal stents (BMS) at stent edges in patients with acute myocardial infarction (AMI). Methods and results: Clinical, angiographic, intravascular ultrasound (lVUS) and virtual histology (VH)-IVUS results were obtained and analysed in 20 SES and 20 BMS AMI patients at the index procedure and at nine months follow-up. Quantitative angiography and IVUS showed a trend toward decreases in mean lumen diameter, vessel volume, m... Abstract
Cited 68 times since 2009 (4.6 per year) source: EuropePMC
American journal of physiology. Heart and circulatory physiology, Volume 297, Issue 5, 25 4 2009, Pages H1606-16 Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. Umar S, de Visser YP, Steendijk P, Schutte CI, Laghmani el H, Wagenaar GT, Bax WH, Mantikou E, Pijnappels DA, Atsma DE, Schalij MJ, van der Wall EE, van der Laarse A
Pulmonary arterial hypertension (PAH) is a chronic lung disease that leads to right ventricular (RV) hypertrophy (RVH), remodeling, and failure. We tested treatment with bone marrow-derived mesenchymal stem cells (MSCs) obtained from donor rats with monocrotaline (MCT)-induced PAH to recipient rats with MCT-induced PAH on pulmonary artery pressure, lung pathology, and RV function. This model was chosen to mimic autologous MSC therapy. On day 1, PAH was induced by MCT (60 mg/kg) in 20 female Wist... Abstract
Cited 57 times since 2009 (3.9 per year) source: EuropePMC
Circulation. Heart failure, Volume 2, Issue 6, 6 1 2009, Pages 643-653 A new direction for cardiac regeneration therapy: application of synergistically acting epicardium-derived cells and cardiomyocyte progenitor cells. Winter EM, van Oorschot AA, Hogers B, van der Graaf LM, Doevendans PA, Poelmann RE, Atsma DE, Gittenberger-de Groot AC, Goumans MJ
Background: Adult human epicardium-derived cells (EPDCs), transplanted into the infarcted heart, are known to improve cardiac function, mainly through paracrine protection of the surrounding tissue. We hypothesized that this effect might be further improved if these supportive EPDCs were combined with cells that could possibly supply the ischemic heart with new cardiomyocytes. Therefore, we transplanted EPDCs together with cardiomyocyte progenitor cells that can generate mature cardiomyocytes in... Abstract
Cited 26 times since 2009 (1.8 per year) source: EuropePMC
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, Volume 74, Issue 2, 1 1 2009, Pages 335-343 In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program. Hassan AK, Liem SS, van der Kley F, Bergheanu SC, Wolterbeek R, Bosch J, Bootsma M, Zeppenfeld K, van der Laarse A, Atsma DE, Jukema JW, Schalij MJ
Objectives: Our aim was to evaluate the effects of early abciximab administration in the ambulance on immediate, short, and long term outcomes. Background: Early abciximab administration before primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is recommended in practice guidelines. However, optimal timing of administration remains indistinct. Methods: Within a fixed protocol for PPCI, December 2006 was the cut-off point for this prospective... Abstract
Cited 17 times since 2009 (1.1 per year) source: EuropePMC
Circulation. Arrhythmia and electrophysiology, Volume 2, Issue 5, 7 1 2009, Pages 524-530 New ECG criteria in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Cox MG, van der Smagt JJ, Wilde AA, Wiesfeld AC, Atsma DE, Nelen MR, Rodriguez LM, Loh P, Cramer MJ, Doevendans PA, van Tintelen JP, de Bakker JM, Hauer RN
Background: Desmosomal changes, electric uncoupling, and surviving myocardial bundles in fibrofatty tissue characterize arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). Resultant activation delay is pivotal for reentry and thereby ventricular tachycardia (VT). Current task force criteria (TFC) for diagnosis have limited sensitivity. The aim of this study was to assess the diagnostic value of additional criteria on activation delay and VT to improve identification of affected i... Abstract
Cited 177 times since 2009 (11.8 per year) source: EuropePMC
JAMA, Volume 301, Issue 19, 1 1 2009, Pages 1997-2004 Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. van Ramshorst J, Bax JJ, Beeres SL, Dibbets-Schneider P, Roes SD, Stokkel MP, de Roos A, Fibbe WE, Zwaginga JJ, Boersma E, Schalij MJ, Atsma DE
Context: Previous studies have suggested that bone marrow cell injection may improve myocardial perfusion and left ventricular (LV) function in patients with chronic myocardial ischemia. Objective: To investigate the effect of intramyocardial bone marrow cell injection on myocardial perfusion and LV function in patients with chronic myocardial ischemia. Design, setting, and patients: Randomized, double-blind, placebo-controlled trial at a Netherlands university hospital, May 1, 2005-March 3, 200... Abstract
Cited 8 times since 2009 (0.5 per year) source: EuropePMC
The American journal of cardiology, Volume 103, Issue 11, 22 4 2009, Pages 1592-1597 Relation of immediate decrease in ventricular septal strain after alcohol septal ablation for obstructive hypertrophic cardiomyopathy to long-term reduction in left ventricular outflow tract pressure gradient. van Ramshorst J, Mollema SA, Delgado V, van der Wall EE, Schalij MJ, Atsma DE, Bax JJ
Alcohol septal ablation (ASA) aims to decrease left ventricular outflow tract (LVOT) obstruction in patients with obstructive hypertrophic cardiomyopathy (HC). To date, no diagnostic variables at baseline are available to predict long-term success of the procedure. We hypothesized that an immediate decrease in septal longitudinal strain after ASA would be associated with sustained LVOT gradient decrease after 6 months. ASA was performed in 22 patients with HC and severe drug-refractory symptoms.... Abstract
Cited 10 times since 2009 (0.7 per year) source: EuropePMC
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Volume 4, Issue 5, 1 1 2009, Pages 662-668 Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: prospective study comparing pre- and in-hospital abciximab pretreatment. Hassan AK, Jukema JW, van der Laarse A, Hasan-Ali H, Wolterbeek R, van der Kley F, Spano F, Atsma DE, Schalij MJ
Aims: This study was performed to assess the incidence, patient characteristics and predictors of aborted myocardial infarction (MI) in patients with ST-segment elevation MI (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods and results: We enrolled 179 consecutive patients with STEMI within a fixed protocol for PPCI (Leiden MISSION! project); 90 patients received abciximab bolus in the hospital (in-hospital group) and 89 patients received abciximab bolus in the ambula... Abstract
Cited 36 times since 2009 (2.3 per year) source: EuropePMC
The American journal of cardiology, Volume 103, Issue 6, 24 4 2009, Pages 779-784 Usefulness of peak troponin-T to predict infarct size and long-term outcome in patients with first acute myocardial infarction after primary percutaneous coronary intervention. Hassan AK, Bergheanu SC, Hasan-Ali H, Liem SS, van der Laarse A, Wolterbeek R, Atsma DE, Schalij MJ, Jukema JW
In acute myocardial infarction cardiac troponin-T (cTnT) is the preferred biomarker to detect myocardial necrosis. Our aim was to investigate the prognostic value of peak plasma cTnT in patients with ST-elevation myocardial infarction treated by primary percutaneous coronary intervention (PCI). Patients were eligible if ST-elevation myocardial infarction symptoms started Abstract
Cited 2 times since 2009 (0.1 per year) source: EuropePMC
Circulation research, Volume 104, Issue 1, 1 1 2009, Pages e8 Response to the letter by Rose et al. Pijnappels DA, Schalij MJ, Atsma DE
Cited 2 times since 2008 (0.1 per year) source: EuropePMC
Journal of internal medicine, Volume 264, Issue 6, 6 1 2008, Pages 571-585 Reduced leucocyte cholesteryl ester transfer protein expression in acute coronary syndromes. Ye D, Kraaijeveld AO, Grauss RW, Willems SM, van Vark-van der Zee LC, de Jager SC, Jauhiainen M, Kuivenhoven JA, Dallinga-Thie GM, Atsma DE, Hogendoorn PC, Biessen EA, Van Berkel TJ, Jukema JW, van Eck M
Objective: Cholesterol ester transfer protein (CETP) plays an important role in HDL cholesterol metabolism. Leucocytes, including monocyte-derived macrophages in the arterial wall synthesize and secrete CETP, but its role in atherosclerosis is unclear. The aim of the current study was to investigate the effect of acute coronary syndromes (ACS) on leucocyte CETP expression. Research design: Peripheral blood mononuclear cells (PBMCs) were freshly isolated from hospitalized ACS patients displaying... Abstract
Cited 19 times since 2008 (1.2 per year) source: EuropePMC
European journal of heart failure, Volume 10, Issue 9, 2 1 2008, Pages 878-883 Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy. Umar S, Bax JJ, Klok M, van Bommel RJ, Hessel MH, den Adel B, Bleeker GB, Henneman MM, Atsma DE, van der Wall EE, Schalij MJ, van der Laarse A
Background: In patients with heart failure cardiac resynchronization therapy (CRT) leads to reverse ventricular remodelling. Aim: To evaluate whether myocardial collagen metabolism in patients with heart failure is implicated in adverse ventricular remodelling and response to CRT. Methods: Collagen synthesis and degradation were assessed from the concentrations of aminoterminal propeptides of type I and type III collagen (PINP and PIIINP) and carboxyterminal telopeptide of type I collagen (ICTP)... Abstract